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INTRODUCTION
Cyclooxygenase-2 (COX-2) has been associated with the
biology of tumors including carcinogenesis, inhibition of
apoptosis, proliferation, promotion of angiogenesis, enhanced
invasiveness, immune modulation, and increased mutagen-
esis (1, 2). Clinical studies have shown that COX-2 overex-
pression might be related to the extent of tumors at diagno-
sis and treatment outcomes of several cancers (3-12). In
addition, COX-2 overexpression has been reported to short-
en the disease-free and overall survival after radiation thera-
py (RT) in patients with cervical cancer (7, 8, 10). Recently,
COX-2 overexpression has been reported to reduce the tumor
response to RT in esophageal cancer, cervical cancer and rec-
tal cancer (13-16). Inhibitory effect of COX-2 on apoptosis
is thought to be the cause of the reduced response rate in such
cases.
In squamous cell carcinoma (SCC) of the uterine cervix,
COX-2 overexpression has been reported to have an adverse
effect on tumor response in two studies (14, 16); however,
the relationship between COX-2 expression and tumor res-
ponse remains to be elucidated. In these studies, the meth-
ods for evaluation of the tumor response after RT were not
described, and possible confounding factors such as tumor
volume were not analyzed. Traditional methods including
gynecological examination or computerized tomography
scanning have limitations with regard to the evaluation of
responses; they cannot exactly determine alterations in the
extent of tumors. However, assessment of tumors using mag-
netic resonance imaging (MRI) could offer more accurate and
objective information compared to clinical evaluations (17). 
In this study, we used MRI to evaluate the tumor response
to RT, and investigated the correlation between COX-2 ex-
pression and tumor response in patients with SCC of the uter-
ine cervix treated with RT.
MATERIALS AND METHODS
Patient selection
We enrolled 57 patients treated with curative radiotherapy
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The Effect of Cyclooxygenase-2 Expression on Tumor Volume Response
in Patients Treated with Radiotherapy for Uterine Cervical Cancer
We investigated the correlation between Cyclooxygenase-2 (COX-2) expression
and the tumor response in patients with cervical cancer that were treated with cura-
tive radiotherapy (RT). Fifty-seven patients with squamous cell carcinoma were treat-
ed with concurrent radiochemotherapy (CRCT, n=29) or RT alone (n=28). The res-
ponse of each patient was evaluated by three serial Magnetic Resonance Imaging
examinations: before the start of RT, at four weeks after the start of RT (mid-RT)
and at four weeks after the completion of RT (post-RT). Forty-three patients had
positive COX-2 expression. The COX-2 negative patients achieved a higher rate
of complete response (CR) at mid-RT than did the COX-2 positive patients (28.6%
vs. 7.0%, P=0.054), but not at post-RT (64.3% vs. 69.8%). The initial tumor volume
was a significant predictor of CR at mid-RT (P=0.003) and post-RT (P=0.004). The
multivariate analysis showed that the initial tumor volume (at mid-RT and post-RT)
and CRCT (at post-RT) were significant predictors of CR; however, the COX-2 ex-
pression was not. In conclusion, the COX-2 expression status has no significant
correlation with the tumor response. Further studies on the changes in COX-2 ex-
pression levels during RT may be helpful for determination of its role in the tumor
response to treatment and patient prognosis.
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for SCC of the uterine cervix from 1997 to 2004 at Samsung
Medical Center. All patients had three serial MRIs performed
before, during and after radiotherapy and had an available
paraffin block sample for immunohistochemical staining.
The patient’s age range was from 34 to 83 yr with a median
age of 61 yr. The number of patients with FIGO stages I, II,
III, and IV was 7, 33, 12, and 5, respectively. Lymph node
metastasis was suspected in the pelvis in 29 patients and the
paraaortic region in five patients. The mean tumor size was
4.8 cm (range 1.2-8.2 cm).
Treatment
All patients were treated with external beam RT plus intra-
cavitary brachytherapy (ICR). The external beam RT was
performed with a 15-MV photon delivered daily in 1.8 Gy,
five fractions per week. Whole-pelvic external irradiation was
given up to a dose of 39.6 Gy (for stage IB or IIA) or 45 Gy
(for stage IIB, III, and IV), and then midline shielding was
used. The total dose delivered to the parametrium ranged from
45 Gy to 66.6 Gy (median 50.4 Gy). Patients with paraaor-
tic lymph node metastasis were treated with extended pelvic
RT, including the paraaortic lymph node region up to 45 Gy.
High dose rate ICR using an 192Ir source was used to deliver
a total dose of 24 Gy at point A with six insertions, two frac-
tions per week.
Twenty-nine patients (50.9%) received concurrent radio-
chemotherapy (CRCT). Eighteen patients were given con-
current and adjuvant chemotherapy including cisplatin (60
mg/m2) plus 5-fluorouracil (1,000 mg/m2 in a continuous
infusion over 96 hr) every three weeks; a median of three cycles
was administered (range 1-6 cycles). Eleven patients were
given weekly cisplatin (30 mg/m2) concurrently with RT.
The median overall treatment time for all patients was 55
days (range 37-85 days).
Response evaluation
The patients underwent three serial MRI examinations with-
in four weeks before the start of RT (pre-RT), at four weeks
after the start of RT (mid-RT) and at four weeks after the com-
pletion of RT (post-RT). The tumor volume of each MRI
examination was calculated by multiplying the sum of the
areas by the slice thickness of T2-weighted axial or sagittal
images using the Picture Archiving Communication System
(General Electric Medical Systems, Milwaukee, WI, U.S.A.).
The mid-RT and post-RT responses were classified into four
categories: complete response (CR) was the complete disap-
pearance of the primary cervical tumor, partial response was
a reduction of 50% or more in the pretreatment volume of
the primary cervical tumor; stable disease was a reduction of
less than 50% or an increase of less than 25%; progressive
disease was an increase of 25% or more.
Immunohistochemical staining of COX-2
Immunohiostochemical staining was performed with a
COX-2 monoclonal antibody (Cayman Chemical, Ann Arbor,
MI, U.S.A.). Two pathologists analyzed the immunostaining
without knowledge of the patient outcome. They evaluated
the slides based on the percentage of tumor cells stained as
follows: 0, totally negative; 1, <10% reactive; 2, 10-50%
reactive; 3, >50% reactive. Scores 0 and 1 were regarded as
negative and scores 2 and 3 as positive. Cases with discordant
results were discussed until a consensus was reached (Fig. 1).
Statistical analysis
The correlations between patient characteristics and COX-
2 expression were evaluated by the Fisher’s exact test. The
relationships between variables and tumor response at mid-
RT and post-RT were evaluated by the same method. The
generalized estimating equation was used to verify the sig-
Fig. 1. Immunohistochemical staining of COX-2. (A) negative (<10% of distribution of immunoreactivity), (B) positive (≥10% of distribu-
tion of immunoreactivity) (original magnification ×200).
A B1172 M.K. Kang, W. Park, Y.-L. Choi, et al.
nificance of the change of the CR rate from mid-RT to post-
RT according to the treatment modality. In addition, we used
the multiple logistic regression analysis to evaluate signifi-
cant predictors of CR at mid-RT and post-RT. P values of
less than 0.05 were considered statistically significant. All
statistical analyses were performed with the SAS
� System
(SAS 8.0, SAS Institute Inc., Cary, NC, U.S.A.).
RESULTS
Tumor response
The mean tumor volume of all patients at pre-RT, mid-RT
and post-RT was 58 mL (range 1.1-166.4 mL), 15.6 mL (range
0-132.6 mL) and 14.2 mL (range 0-96.8 mL), respectively.
Seven patients (12.3%) achieved CR at mid-RT and 39 pati-
ents (68.4%) at post-RT.
COX-2 expression
COX-2 expression was positive in 43 patients (75.4%).
COX-2 expression was not related to age, hemoglobin level,
initial tumor volume, the FIGO stage or treatment modali-
ty (Table 1). Evaluation based on the initial tumor size showed
that COX-2 positive cases were more common in patients
with larger tumors (>4 cm); however, the difference was mar-
ginally significant (P=0.059).
Tumor response according to COX-2 expression
At mid-RT, CR was more common in COX-2 negative
patients than in COX-2 positive patients (28.6% vs. 7.0%,
respectively) but the correlation was marginally significant
(P=0.054). At post-RT, CR was achieved in 64.3% of COX-2
negative patients and in 69.8% of COX-2 positive patients
(P=0.747).
Table 2 shows the relationship between COX-2 expression
and tumor response according to the initial tumor volume
or treatment modality. For patients with a small pretreatment
tumor volume (≤32 mL), the COX-2 negative tumors tend-
Variables
No. of patients (%)
P value
COX-2 (-) COX-2 (+)
Table 1. Patient characteristics according to COX-2 expression
COX-2, cyclooxygenase-2.
Variables
No. of patients (%)
4 weeks after initiation of RT
CR Non-CR P value
4 weeks after completion of RT
CR Non-CR P value
Table 2. Tumor volume responses during and after radiotherapy according to COX-2 expression
RT, radiation therapy; CR, complete response; COX-2, cyclooxygenase-2; CRCT, concurrent radiochemotherapy.
All patients
COX-2 (-) 4 (28.6) 10 (71.4) 0.054 9 (64.3) 5 (35.7) 0.747
COX-2 (+) 3 (7.0) 40 (93.0) 30 (69.8) 13 (30.2)
Initial volume ≤32 mL
COX-2 (-) 4 (66.7) 2 (33.3) 0.057 5 (83.3) 1 (16.7) 1.000
COX-2 (+) 2 (16.7) 10 (83.3) 12 (100.0) 0 (0.0)
Initial volume >32 mL
COX-2 (-) 0 (0.0) 8 (100.0) 1.000 4 (50.0) 4 (50.0) 1.000
COX-2 (+) 1 (3.2) 30 (96.8) 18 (58.1) 13 (41.9)
RT alone
COX-2 (-) 4 (44.4) 5 (55.6) 0.026 5 (55.6) 4 (44.4) 1.000
COX-2 (+) 1 (5.3) 18 (94.7) 12 (63.2) 7 (36.8)
CRCT
COX-2 (-) 0 (0) 5 (100) 1.000 4 (80.0) 1 (20.0) 1.000
COX-2 (+) 2 (8.3) 22 (91.7) 18 (75.0) 6 (25.0)
Age (yr)
≤60 5 (35.7) 22 (51.2) 0.369
>60 9 (64.3) 21 (48.8)
Hemoglobin
≤10 g/dL 2 (84.6) 12 (71.4) 0.477
>10 g/dL 11 (15.4) 30 (28.6)
Unknown 1 (50.0) 1 (50.0)
Initial tumor size
≤4 cm 8 (57.1) 12 (27.9) 0.059
>4 cm 6 (42.9) 31 (72.1)
Initial tumor volume
≤32 mL 6 (42.9) 12 (27.9) 0.334
>32 mL 8 (57.1) 31 (72.1)
FIGO stage
IB-II 8 (57.1) 32 (74.4) 0.314
III-IVa 6 (42.9) 11 (25.6)
Treatment
Radiotherapy 9 (64.3) 19 (44.2) 0.230
Radiochemotherapy 5 (35.7) 24 (55.8) COX-2 and Tumor Response in Cervical Cancer 1173
ed to achieve a higher rate of CR at mid-RT than COX-2
positive tumors (P=0.057); however, there was no difference
in the CR rate at post-RT. In patients who received RT alone,
COX-2 negative tumors achieved a significantly higher rate
of CR than did COX-2 positive tumors at mid-RT (44.4%
vs. 5.3%, P=0.026); however, this was not observed at post-
RT. The tumor response was related to COX-2 expression
in neither patients with a large pretreatment tumor volume
(>32 mL) nor the CRCT group.
Factors affecting the tumor response
Tables 3, 4 show the relationship between the variables and
tumor response during and after RT. Patients with a small
pretreatment tumor volume achieved a higher rate of CR
both at mid-RT (33.3% for ≤32 mL vs. 2.6% for >32 mL,
P=0.003) and at post-RT (94.4% for ≤32 mL vs. 56.4% for
>32 mL, P=0.005). Patients with a small pretreatment tumor
size achieved similar results at mid-RT (P=0.006) but not
at post-RT.
According to the treatment modalities, the CR rate was
not different at mid-RT and post-RT. However, the CR rate
increased more in the CRCT group from 6.9% at mid-RT to
75.9% at post-RT than in the RT alone group from 17.9%
to 60.7%; these findings were marginally significant (P=
0.057).
Factors affecting the tumor response in the multiple
logistic regression analysis
The multivariate analysis revealed that the initial tumor
volume and concurrent chemotherapy were significant pre-
dictors of CR at mid-RT and post-RT (Table 5). Tumors with
an initial volume >32 mL had a lower probability of CR at
mid-RT (odds ratio [OR]=0.052; 95% confidence interval
[CI], 0.005-0.588) and post-RT (OR=0.037; 95% CI, 0.004-
0.379) compared to those with an initial volume ≤32 mL.
The patients treated with CRCT had a greater probability of
Variable
No. of patients (%)
P value
CR Non-CR
Table 3. Tumor response at 4 weeks after initiation of radiother-
apy for all patients
CR, complete response.
Variable
No. of patients (%)
P value
CR Non-CR
Table 4. Tumor response at 4 weeks after radiotherapy for all
patients
CR, complete response.
Variable
4 weeks after initiation of RT
OR (95% CI) P value
4 weeks after completion of RT
OR (95% CI) P value
Table 5. Multiple logistic regression analysis of the initial tumor volume, COX-2, and concurrent chemotherapy as predictive factors
of complete response
RT, radiation therapy; OR, odds ratio; CI, confidence interval; COX-2, cyclooxygenase-2.
Initial tumor volume (>32 mL vs. ≤32 mL) 0.052 (0.005-0.588) 0.017 0.037 (0.004-0.379) 0.006
COX-2 expression (positive vs. negative) 0.188 (0.023-1.504) 0.115 2.042 (0.436-9.569) 0.365
Concurrent chemotherapy (yes vs. no) 1.165 (0.127-10.709) 0.892 4.152 (1.081-15.948) 0.038
Age (yr)
≤60 19 (70.4) 8 (29.6) 0.784
>60 20 (66.7) 10 (33.3)
Hemoglobin
≤10 g/dL 8 (57.1) 6 (42.8) 0.510
>10 g/dL 29 (70.7) 12 (29.3)
Unknown 2 (100) 0 (0)
Tumor size
≤4 cm 15 (75.0) 5 (30.0) 0.555
>4 cm 24 (64.9) 13 (35.1)
Initial tumor volume
≤32 mL 17 (94.4) 1 (5.6) 0.005
>32 mL 22 (56.4) 17 (43.6)
FIGO stage
IB-II 29 (72.5) 11 (27.5) 0.359
III-IVa 10 (58.8) 7 (41.9)
Treatment
Radiotherapy 17 (60.7) 11 (39.3) 0.263
Radiochemotherapy 22 (75.9) 7 (24.1)
Age (yr)
≤60 3 (11.1) 24 (88.9) 1.000
>60 4 (13.3) 26 (86.7)
Hemoglobin
≤10 g/dL 1 (7.1) 13 (92.9) 1.000
>10 g/dL 5 (12.2) 36 (87.8)
Unknown 1 (50.0) 1 (50.0)
Tumor size
≤4 cm 6 (30.0) 14 (70.0) 0.006
>4 cm 1 (2.7) 36 (97.3)
Initial tumor volume
≤32 mL 6 (33.3) 12 (66.7) 0.003
>32 mL 1 (2.6) 38 (97.4)
FIGO stage
IB-II 6 (15.0) 34 (85.0) 0.662
III-IVa 1 (5.9) 16 (94.1)
Treatment
Radiotherapy 5 (17.9) 23 (82.1) 0.253
Radiochemotherapy 2 (6.9) 27 (93.1)1174 M.K. Kang, W. Park, Y.-L. Choi, et al.
CR at post-RT than did those treated with RT alone (OR=
4.152; 95% CI, 1.081-15.948). The COX-2 expression sta-
tus was not related to tumor response.
DISCUSSION
The tumor volume prior to RT is a known prognostic fac-
tor for cervical cancer, but Gong et al. (18) confirmed an expo-
nential relationship between tumor regression rates (TRR)
and time regardless of the tumor volume by estimating TRR
during external beam RT with serial MRI. They suggested
that tumors with a small pretreatment volume have a high-
er probability of early disappearance after RT. We also found
that small volume tumors achieved a higher rate of CR at
mid-RT and post-RT compared to large volume tumors.
Currently, chemotherapy is used concurrently with RT to
improve the treatment results for patients with locally ad-
vanced cervical cancer (19, 20). Ohara et al. (21) investigat-
ed the difference of TRR according to the treatment modal-
ity (CRCT vs. RT alone) by fitting an exponential regression
equation to the respective curve of each patient. Although
TRR was not significantly different between the CRCT group
(median, 0.032 per day) and the RT alone group (median,
0.024 per day), rapid TRR (>0.05 per day) was more com-
mon in the CRCT group. In addition, TRR for large tumors
(>5 cm in diameter) was greater in the CRCT group. In a
randomized trial reported by Keys et al. (22), the rate of resid-
ual disease in hysterectomy specimens at three to six weeks
after treatment was lower in the CRCT group compared to
the RT alone group. In our study, the CR rate was not differ-
ent according to the use of chemotherapy. However, the ini-
tial tumor volume of the CRCT group was significantly larger
than that of the RT alone group (average 70.9 mL vs. 44.6
mL, P=0.034). Therefore, we analyzed the extent of change
of the CR rate from mid-RT to after-RT, and the increase of
the CR rate was prominent in the CRCT group. The CR rate
at post-RT was higher in the CRCT group than in the RT
alone group where the CR rate was higher at mid-RT. It is
therefore reasonable to conclude that chemotherapy acceler-
ated the tumor response to RT.
COX-2 overexpression has been accepted as an indepen-
dent prognostic factor for recurrence and survival in patients
with cervical cancer (7, 8, 10). Kim et al. (8) reported that
the 5-yr overall and disease free survival was worse in COX-
2 positive patients than in COX-2 negative patients, and
COX-2 overexpression was the only significant prognostic
factor in the multivariate analysis. Chen et al. (10) also report-
ed similar results. COX-2 overexpression was related to a
reduced tumor response to radiotherapy in esophageal and
rectal cancer (13, 15). For SCC of the esophagus, COX-2 neg-
ative patients achieved a higher CR rate after preoperative
radiochemotherapy (60% vs. 0%, P=0.01); however, this result
is limited by the small number of patients and confounding
factors affecting tumor response. In rectal cancer, COX-2 over-
expression in pretreatment biopsies was related to a poor res-
ponse to neoadjuvant radiochemotherapy (P=0.026) (15).
Two studies investigating the correlation between COX-
2 overexpression and complete remission after RT have been
reported in patients with uterine cervical cancer (14, 16). Kim
et al. (14) reported that all COX-2 negative patients achieved
a CR; however, 83% of COX-2 positive patients with SCC
and 68% of those with adenocarcinoma achieved a CR (P<
0.001). Ishikawa et al. (16) found that COX-2 overexpres-
sion before RT was related to reduced apoptosis after 9 Gy,
and tumors without COX-2 overexpression achieved a higher
rate of CR after RT although this was not statistically signif-
icant (80% vs. 59%, P=0.12). In our study, multiple logistic
regression analysis showed that the COX-2 status was not a
predictive factor of a CR. Although the COX-2 status seemed
to be correlated with tumor response in some selected sub-
groups, the tumors that achieved a CR, at mid-RT, were sig-
nificantly smaller than the tumors that did not achieve a CR
(10.5±14.1 mL vs. 64.6±46.5 mL, P<0.001), Further-
more, COX-2 negative tumors, in the small volume group
and RT alone group, were significantly smaller than COX-
2 positive tumors in each of the subgroups. This could have
caused COX-2 overexpression to be misinterpreted as a sig-
nificant predictor of the tumor response. However, we can-
not conclude that COX-2 does not have influence on tumor
response to radiotherapy on the basis of our study results due
to the retrospective study design and potential for selection
bias.
Although there is no data on the change of COX-2 protein
expression during radiotherapy in patients with cervical can-
cer, COX-2 protein expression increased after single or frac-
tionated irradiation in PC-3 cells in vitro (23, 24), and after
radiotherapy for rectal cancer patients in vivo (25-29). For
the patients with rectal cancer treated with preoperative radio-
therapy, with or without chemotherapy, the distribution of
COX-2 positive tumors or the intensity of COX-2 protein
expression increased, and even the tumors without COX-2
expression newly expressed the COX-2 protein. One study
reported that the initial COX-2 expression was not correlated
with tumor regression (28). However, another study reported
that the intensity of COX-2 protein expression, after radio-
chemotherapy, was inversely correlated with tumor regres-
sion (29). Therefore, COX-2 protein expression in patients
with cervical cancer might also increase during radiothera-
py. Investigation of the change in COX-2 expression levels
during RT, by repeated biopsies, might be indicated to deter-
mine the relationship between COX-2 expression and the
tumor response.
In conclusion, the results of this study show no correlation
between the pretreatment COX-2 expression status and the
tumor response. However, the COX-2 expression status is
known as an important prognostic factor in patients with cer-
vical cancer based on previous studies. Therefore, further stud-COX-2 and Tumor Response in Cervical Cancer 1175
ies are needed to clarify the alteration of COX-2 expression
levels during RT to determine its association with the tumor
response to treatment and patient prognosis.
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